A study of aging mice showed that voluntary exercise over 30 days increased striatal dopamine release and improved motor ...

Experimental therapy deramiocel outperformed a placebo at improving measures of arm and heart health in people with DMD in a ...

Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...

Cosmo Pharmaceuticals attracted welcome attention from investors and other market watchers after coming out with topline ...

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Capricor Therapeutics has seen its modeled fair value estimate jump from about $20.60 to roughly $44.56 per share, as analysts grow more confident in Deramiocel's path from the clinic to ...

The latest announcement is out from Capricor Therapeutics ( (CAPR) ).

Shares of Capricor Therapeutics CAPR have skyrocketed 281.9% this week. The massive stock price surge was observed after the ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

Martin Shkreli says QCLS stock could hit $100 in the near-term. He has fairly recently been proven wrong on Capricor Therapeutics.